Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes Review uri icon

Overview

MeSH Major

  • Diabetes Complications
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex

abstract

  • This meta-analysis, including the entire large-scale trial experience of intravenous platelet GP IIb/IIIa inhibitors for the medical management of non-ST-segment-elevation ACS, shows that these agents may significantly reduce mortality at 30 days in diabetic patients. Although not based on a randomized assessment, the survival benefit appears to be of greater magnitude in patients undergoing PCI. Therefore, the use of platelet GP IIb/IIIa inhibitors should be strongly considered in diabetic patients with ACS.

publication date

  • December 4, 2001

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 11733392

Additional Document Info

start page

  • 2767

end page

  • 71

volume

  • 104

number

  • 23